诺比列素通过激活PPARγ和PGC1α减轻心肌梗死后的病理性心脏重构。

IF 3.5 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
PPAR Research Pub Date : 2021-08-06 eCollection Date: 2021-01-01 DOI:10.1155/2021/9947656
Yufei Zhou, Ting Yin, Mengsha Shi, Mengli Chen, Xiaodong Wu, Kai Wang, Iokfai Cheang, Yanxiu Li, Hongcai Shang, Haifeng Zhang, Xinli Li
{"title":"诺比列素通过激活PPARγ和PGC1α减轻心肌梗死后的病理性心脏重构。","authors":"Yufei Zhou,&nbsp;Ting Yin,&nbsp;Mengsha Shi,&nbsp;Mengli Chen,&nbsp;Xiaodong Wu,&nbsp;Kai Wang,&nbsp;Iokfai Cheang,&nbsp;Yanxiu Li,&nbsp;Hongcai Shang,&nbsp;Haifeng Zhang,&nbsp;Xinli Li","doi":"10.1155/2021/9947656","DOIUrl":null,"url":null,"abstract":"<p><strong>Materials and methods: </strong>C57BL/6 mice were treated with coronary artery ligation to generate an MI model, followed by treatment for 3 weeks with NOB (50 mg/kg/d) or vehicle (50 mg/kg/d), with or without the peroxisome proliferator-activated receptor gamma (PPAR<i>γ</i>) inhibitor T0070907 (1 mg/kg/d). Cardiac function (echocardiography, survival rate, Evans blue, and triphenyl tetrazolium chloride staining), fibrosis (Masson's trichrome staining, quantitative real-time polymerase chain reaction (qRT-PCR), and western blot (WB)), hypertrophy (haematoxylin-eosin staining, wheat germ agglutinin staining, and qRT-PCR), and apoptosis (WB and terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) staining) were evaluated. Hypoxia-induced apoptosis (TUNEL, WB) and phenylephrine- (PE-) induced pathological hypertrophy (immunofluorescence staining, qRT-PCR) models were established in primary neonatal rat ventricular myocytes (NRVMs). The effects of NOB with or without T0070907 were examined for the expression of PPAR<i>γ</i> and PPAR<i>γ</i> coactivator 1<i>α</i> (PGC1<i>α</i>) by WB in mice and NRVMs. The potential downstream effectors of PPAR<i>γ</i> were further analyzed by WB in mice.</p><p><strong>Results: </strong>Following MI in mice, NOB intervention enhanced cardiac function across three predominant dimensions of pathological cardiac remodeling, which reflected in decreasing cardiac fibrosis, apoptosis, and hypertrophy decompensation. NOB intervention also alleviated apoptosis and hypertrophy in NRVMs. NOB intervention upregulated PPAR<i>γ</i> and PGC1<i>α in vivo</i> and <i>in vitro</i>. Furthermore, the PPAR<i>γ</i> inhibitor abolished the protective effects of NOB against pathological cardiac remodeling during the progression from MI to CHF. The potential downstream effectors of PPAR<i>γ</i> were nuclear factor erythroid 2-related factor 2 (Nrf-2) and heme oxygenase 1 (HO-1).</p><p><strong>Conclusions: </strong>Our findings suggested that NOB alleviates pathological cardiac remodeling after MI via PPAR<i>γ</i> and PGC1<i>α</i> upregulation.</p>","PeriodicalId":20439,"journal":{"name":"PPAR Research","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2021-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373512/pdf/","citationCount":"9","resultStr":"{\"title\":\"Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPAR<i>γ</i> and PGC1<i>α</i>.\",\"authors\":\"Yufei Zhou,&nbsp;Ting Yin,&nbsp;Mengsha Shi,&nbsp;Mengli Chen,&nbsp;Xiaodong Wu,&nbsp;Kai Wang,&nbsp;Iokfai Cheang,&nbsp;Yanxiu Li,&nbsp;Hongcai Shang,&nbsp;Haifeng Zhang,&nbsp;Xinli Li\",\"doi\":\"10.1155/2021/9947656\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Materials and methods: </strong>C57BL/6 mice were treated with coronary artery ligation to generate an MI model, followed by treatment for 3 weeks with NOB (50 mg/kg/d) or vehicle (50 mg/kg/d), with or without the peroxisome proliferator-activated receptor gamma (PPAR<i>γ</i>) inhibitor T0070907 (1 mg/kg/d). Cardiac function (echocardiography, survival rate, Evans blue, and triphenyl tetrazolium chloride staining), fibrosis (Masson's trichrome staining, quantitative real-time polymerase chain reaction (qRT-PCR), and western blot (WB)), hypertrophy (haematoxylin-eosin staining, wheat germ agglutinin staining, and qRT-PCR), and apoptosis (WB and terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) staining) were evaluated. Hypoxia-induced apoptosis (TUNEL, WB) and phenylephrine- (PE-) induced pathological hypertrophy (immunofluorescence staining, qRT-PCR) models were established in primary neonatal rat ventricular myocytes (NRVMs). The effects of NOB with or without T0070907 were examined for the expression of PPAR<i>γ</i> and PPAR<i>γ</i> coactivator 1<i>α</i> (PGC1<i>α</i>) by WB in mice and NRVMs. The potential downstream effectors of PPAR<i>γ</i> were further analyzed by WB in mice.</p><p><strong>Results: </strong>Following MI in mice, NOB intervention enhanced cardiac function across three predominant dimensions of pathological cardiac remodeling, which reflected in decreasing cardiac fibrosis, apoptosis, and hypertrophy decompensation. NOB intervention also alleviated apoptosis and hypertrophy in NRVMs. NOB intervention upregulated PPAR<i>γ</i> and PGC1<i>α in vivo</i> and <i>in vitro</i>. Furthermore, the PPAR<i>γ</i> inhibitor abolished the protective effects of NOB against pathological cardiac remodeling during the progression from MI to CHF. The potential downstream effectors of PPAR<i>γ</i> were nuclear factor erythroid 2-related factor 2 (Nrf-2) and heme oxygenase 1 (HO-1).</p><p><strong>Conclusions: </strong>Our findings suggested that NOB alleviates pathological cardiac remodeling after MI via PPAR<i>γ</i> and PGC1<i>α</i> upregulation.</p>\",\"PeriodicalId\":20439,\"journal\":{\"name\":\"PPAR Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2021-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373512/pdf/\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PPAR Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/9947656\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PPAR Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2021/9947656","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 9

摘要

材料和方法:C57BL/6小鼠冠脉结扎制备心肌梗死模型,随后给予NOB (50 mg/kg/d)或对照(50 mg/kg/d),加或不加过氧化物酶体增殖物激活受体γ (PPARγ)抑制剂T0070907 (1 mg/kg/d)治疗3周。评估心功能(超声心动图、存活率、埃文思蓝染色、三苯基氯化四氮唑染色)、纤维化(马松三色染色、定量实时聚合酶链反应(qRT-PCR)和western blot (WB))、肥厚(苏木精-伊红染色、小麦胚凝集素染色和qRT-PCR)和凋亡(WB和末端脱氧核苷酸转移酶dUTP镍端标记(TUNEL)染色)。建立了新生大鼠心室肌细胞(nrvm)缺氧诱导凋亡(TUNEL, WB)和苯肾上腺素(PE-)诱导病理性肥大(qRT-PCR)模型。研究了NOB加T0070907或不加T0070907对小鼠和nrvm中PPARγ和PPARγ共激活因子1α (PGC1α)表达的影响。用WB进一步分析了PPARγ的潜在下游效应。结果:小鼠心肌梗死后,NOB干预在病理性心脏重塑的三个主要维度上增强了心功能,这反映在心脏纤维化、细胞凋亡和肥厚失代偿的减少。NOB干预还可减轻nrvm的凋亡和肥大。NOB干预在体内和体外上调PPARγ和PGC1α。此外,PPARγ抑制剂消除了NOB在心肌梗死到心力衰竭过程中对病理性心脏重塑的保护作用。PPARγ的潜在下游效应物是核因子-红细胞2相关因子2 (Nrf-2)和血红素加氧酶1 (HO-1)。结论:我们的研究结果表明,NOB通过上调PPARγ和PGC1α来减轻心肌梗死后的病理性心脏重构。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPAR<i>γ</i> and PGC1<i>α</i>.

Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPAR<i>γ</i> and PGC1<i>α</i>.

Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPAR<i>γ</i> and PGC1<i>α</i>.

Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPARγ and PGC1α.

Materials and methods: C57BL/6 mice were treated with coronary artery ligation to generate an MI model, followed by treatment for 3 weeks with NOB (50 mg/kg/d) or vehicle (50 mg/kg/d), with or without the peroxisome proliferator-activated receptor gamma (PPARγ) inhibitor T0070907 (1 mg/kg/d). Cardiac function (echocardiography, survival rate, Evans blue, and triphenyl tetrazolium chloride staining), fibrosis (Masson's trichrome staining, quantitative real-time polymerase chain reaction (qRT-PCR), and western blot (WB)), hypertrophy (haematoxylin-eosin staining, wheat germ agglutinin staining, and qRT-PCR), and apoptosis (WB and terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) staining) were evaluated. Hypoxia-induced apoptosis (TUNEL, WB) and phenylephrine- (PE-) induced pathological hypertrophy (immunofluorescence staining, qRT-PCR) models were established in primary neonatal rat ventricular myocytes (NRVMs). The effects of NOB with or without T0070907 were examined for the expression of PPARγ and PPARγ coactivator 1α (PGC1α) by WB in mice and NRVMs. The potential downstream effectors of PPARγ were further analyzed by WB in mice.

Results: Following MI in mice, NOB intervention enhanced cardiac function across three predominant dimensions of pathological cardiac remodeling, which reflected in decreasing cardiac fibrosis, apoptosis, and hypertrophy decompensation. NOB intervention also alleviated apoptosis and hypertrophy in NRVMs. NOB intervention upregulated PPARγ and PGC1α in vivo and in vitro. Furthermore, the PPARγ inhibitor abolished the protective effects of NOB against pathological cardiac remodeling during the progression from MI to CHF. The potential downstream effectors of PPARγ were nuclear factor erythroid 2-related factor 2 (Nrf-2) and heme oxygenase 1 (HO-1).

Conclusions: Our findings suggested that NOB alleviates pathological cardiac remodeling after MI via PPARγ and PGC1α upregulation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PPAR Research
PPAR Research MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
6.20
自引率
3.40%
发文量
17
审稿时长
12 months
期刊介绍: PPAR Research is a peer-reviewed, Open Access journal that publishes original research and review articles on advances in basic research focusing on mechanisms involved in the activation of peroxisome proliferator-activated receptors (PPARs), as well as their role in the regulation of cellular differentiation, development, energy homeostasis and metabolic function. The journal also welcomes preclinical and clinical trials of drugs that can modulate PPAR activity, with a view to treating chronic diseases and disorders such as dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, and obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信